Bioventus (NASDAQ:BVS) Releases FY 2026 Earnings Guidance

Bioventus (NASDAQ:BVS) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.750-0.790 for the period, compared to the consensus earnings per share estimate of 0.750. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.7 million.

Analyst Ratings Changes

A number of research firms recently weighed in on BVS. CJS Securities began coverage on Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective for the company. Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Barrington Research lifted their price target on Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Finally, Craig Hallum upped their price target on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $14.00.

Bioventus Stock Up 5.0%

BVS stock opened at $10.68 on Wednesday. The stock has a market capitalization of $888.04 million, a P/E ratio of 32.36 and a beta of 0.72. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19. Bioventus has a 1-year low of $5.81 and a 1-year high of $10.76. The business has a fifty day moving average price of $9.23 and a 200-day moving average price of $8.16.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter. The company had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities analysts forecast that Bioventus will post 0.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares of the company’s stock, valued at $395,523.63. This represents a 21.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. State of Wyoming grew its position in shares of Bioventus by 94.9% during the 2nd quarter. State of Wyoming now owns 52,520 shares of the company’s stock valued at $348,000 after acquiring an additional 25,578 shares during the period. Tudor Investment Corp ET AL bought a new position in Bioventus in the 4th quarter worth $347,000. Invesco Ltd. raised its holdings in Bioventus by 52.9% in the 4th quarter. Invesco Ltd. now owns 33,621 shares of the company’s stock worth $250,000 after purchasing an additional 11,639 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after purchasing an additional 1,908 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.